Cannabis Weekly: Curaleaf’s $500M 11.5% Debt Raise, Organigram’s 46% Revenue Jump
Curaleaf secured $500M in 11.5% senior secured notes maturing 2029 to refinance $475M of 8% debt due 2026, extending maturities and boosting global growth. Organigram posted Q1 FY2026 revenue up 46% to $97.3M with net income at $20M, while Tilray secured a UK distribution agreement tapping a £1B medical market.
1. Curaleaf Refinancing Strategy
Curaleaf completed a $500 million private placement of senior secured notes at 11.5% interest maturing February 2029 to refinance $475 million of 8% notes due late 2026, extending debt maturities and providing added flexibility for global expansion initiatives.
2. Organigram Fiscal Q1 Growth
Organigram reported fiscal Q1 2026 gross revenue of $97.3 million (up 46%) and net revenue of $63.5 million (up 49%), with net income reaching $20 million versus a prior-year loss, and adjusted EBITDA rising 273% to $5.3 million, driven by recreational sales and international demand.
3. Tilray UK Pharmaceutical Partnership
Tilray’s CC Pharma unit forged a strategic agreement with Smartway Pharmaceuticals to distribute medical products across the UK, targeting a market estimated at nearly £1 billion, leveraging Smartway’s national network and CC Pharma’s GMP-certified infrastructure to strengthen supply reliability.